BMS receives Health Canada conditional approval for Opdivo-Yervoy combination

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

BRISTOL-MYERS SQUIBB was granted conditional approval by Health Canada for the treatment of previously untreated adults with unresectable or metastatic melanoma using Opdivo and Yervoy. The first-ever combination of two immuno-oncology agents has the potential to increase progression-free survival in certain patients. Health Canada also issued a Notice of Compliance with conditions for the OPDIVO...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Login